Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer-A Retrospective Analysis of Consecutive Patients Data.
Anna Buda-NowakŁukasz KwintaPaweł PotockiAnna Michałowska-KaczmarczykAgnieszka SłowikKamil KonopkaJoanna StrebMaciej KoniewskiPiotr J WysockiPublished in: Journal of clinical medicine (2023)
Metronomic chemo-endocrine therapy with FulVEC regimen represents an interesting option and compares favorably with other approaches in patients' refractory to endocrine treatments. A phase II randomized trial is warranted.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- phase ii
- chronic kidney disease
- clinical trial
- prognostic factors
- peritoneal dialysis
- combination therapy
- stem cells
- open label
- machine learning
- patient reported outcomes
- cancer therapy
- locally advanced
- smoking cessation
- cell therapy
- rectal cancer
- endoplasmic reticulum